Bionomics to pursue Kv1.3 leads alone for now as Merck Serono alliance ends
This article was originally published in Scrip
Executive Summary
Merck Serono and the Australian firm Bionomics have decided to end a collaborative discovery research programme focusing on novel oral small molecule inhibitors of the Kv1.3 ion channel for multiple sclerosis and other autoimmune disorders.